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Xenotropic murine leukemia virus–related gammaret-
rovirus (XMRV) has been recently associated with prostate 
cancer and chronic fatigue syndrome. To identify nucleic acid 
sequences, we examined respiratory secretions by using 
PCR. XMRV-speciﬁ  c sequences were detected in 2%–3% 
of samples from 168 immunocompetent carriers and ≈10% 
of samples from 161 immunocompromised patients.
X
enotropic murine leukemia virus–related gammaret-
rovirus (XMRV) was originally discovered in tissue 
from patients with familial prostate cancer homozygous 
for a missense mutation in the RNase L gene, R462Q (1). 
Detection of viral nucleic acid in tissue sections of cancer-
ous prostate glands and cloning of the viral integration sites 
conﬁ  rmed XMRV as a bona ﬁ  de human infection with a 
murine leukemia virus–related retrovirus (1). Whether 
XMRV is actively involved in prostate cancer tumorigen-
esis or whether it is just a bystander virus (2,3) remains 
unclear.
On the basis of its close homology (up to 94% nt iden-
tity) to endogenous and exogenous full-length sequences 
from Mus musculus mice (1), XMRV most likely originated 
in mice, although they are probably not the current reservoir 
of infection (4). Recent ﬁ  ndings of XMRV sequences in up 
to 67% of peripheral blood mononuclear cells (PBMCs) of 
patients with chronic fatigue syndrome and in 3.4% of PB-
MCs of healthy controls raise the question whether XMRV 
could be a blood-borne pathogen (5). However, the ﬁ  nd-
ing of XMRV in PBMCs from patients with chronic fa-
tigue syndrome is controversial because multiple studies in 
Europe have failed to detect XMRV (6–8). Similarly, fre-
quency of XMRV in prostate cancer samples ranges from 
0 to 23%, depending on geographic restriction of the virus 
or, more likely, diagnostic techniques used (PCR, quanti-
tative PCR, immunohistochemistry) (1–3,9,10). Indirect 
evidence has suggested sexual transmission (9). Questions 
remain about worldwide distribution, host range, transmis-
sion routes, and organ tropism of the virus. To begin to 
answer some of them, we looked for XMRV in respiratory 
samples from 267 patients with respiratory tract infection 
(RTI) and 62 healthy persons.
The Study
During 2006–2009, the 267 samples were collected 
from 3 groups of patients (Table). Group 1 comprised pa-
tients who had traveled from Asia to Germany; location of 
their permanent residency was unknown. Groups 2 and 3 
and the control group comprised only persons from north-
ern Germany. From group 1, a total of 75 sputum and na-
sal swab specimens were collected from patients who had 
unconnected cases of RTI and who had recently traveled 
by air (11). From group 2, a total of 31 bronchoalveolar 
lavage (BAL) samples were collected from patients with 
chronic obstructive pulmonary disease (deﬁ  ned by a forced 
expiratory volume in 1 second/forced vital capacity <70% 
and forced expiratory volume in 1 second <80% of the pre-
dicted value) who had signs of RTI. From group 3, a total 
of 161 BAL and tracheal secretion samples were collected 
from patients with severe RTI and immunosuppression as a 
result of solid organ or bone marrow transplantation. From 
the control group, throat swabs were collected from 52 
healthy persons and BAL samples were collected from 10 
healthy volunteers who had no signs of RTI and no known 
underlying disease. 
All samples were analyzed by culture for pathogenic 
bacteria and fungi and by PCR for rhinoviruses, adenovi-
ruses, enteroviruses, inﬂ  uenza viruses A and B, parainﬂ  u-
enza viruses 1–3, respiratory syncytial virus, cytomegalovi-
rus, Epstein-Barr virus, and human metapneumovirus. All 
samples were tested in duplicates obtained by individual 
RNA extractions. XMRV RNA was reverse transcribed 
from total RNA, after which nested PCR or real-time PCR 
were conducted as recently described (1,12). No serum 
samples were available from these patients to conﬁ  rm the 
results by serologic testing.
For group 1, XMRV-speciﬁ   c sequences were de-
tected with relatively low frequency (2.3%). For group 
2, XMRV-speciﬁ  c sequences were ampliﬁ  ed in 1 BAL 
sample, which was also positive for Staphylococcus au-
reus by routine culture methods. For group 3, XMRV-
speciﬁ  c sequences were detected at a frequency of 9.9%, 
which was signiﬁ  cantly higher than that for the healthy 
control group (3.2%) at the 90% conﬁ  dence level but not 
at the 95% level (p = 0.078, 1 sample t-test). Of 16 group 
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3 samples, 10 showed no signs of co-infection. The re-
maining 6 samples showed co-infection with rhinovirus 
or adenovirus (1 sample each); S. aureus (3 samples); or 
mixed infection with pathogenic fungi, Candida albicans 
and Asperigillus fumigatus (1 sample).
All samples that were positive for XMRV by gag-
nested PCR, together with a set of those that were nega-
tive for XMRV, were retested by real-time PCR. Results 
showed low XMRV RNA concentrations, 103 –104/mL of 
specimen.
To conﬁ  rm the validity of XMRV detection, a subset 
of 6 specimens (3 XMRV positive and 3 XMRV negative) 
were tested by using an alternative PCR assay for viral 
RNA (3) and a C-Type RT Activity Kit (Cavidi, Uppsala, 
Sweden) for type C reverse-transcription activity. XMRV 
sequences from alternative targets in the gag and env re-
gions were conﬁ  rmed in 2 of the 3 XMRV-positive sam-
ples but in none of the controls. One XMRV-positive BAL 
specimen showed an 8-fold increase above background 
of speciﬁ  c type C retroviral reverse-transcriptase activity, 
suggesting presence of active type C retrovirus within this 
sample. This assay is substantially less sensitive than re-
verse transcription–PCR.
All XMRV gag sequences (390-bp fragment) were 
98%–99% identical to previously published XMRV se-
quences from persons with prostate cancer (1,2). Phyloge-
netic analysis showed close clustering (Figure).
Conclusions
XMRV, originally identiﬁ   ed in RNase L–deﬁ  cient 
patients with familial prostate cancer, has gained interest 
since recent work showed its protein expression in as many 
as 23% of prostate cancer cases (10) and XMRV-speciﬁ  c 
sequences were detected in PBMCs of 67% patients with 
chronic fatigue syndrome (5). These results, however, 
could not be conﬁ  rmed by others (6–8). Both studies also 
detected XMRV protein or sequences in their control co-
horts with frequencies of 6% and 4%, respectively.
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Table. Detection of XMRV in respiratory tract secretions from 329 persons* 
Group  Patient median age, y  Underlying disease  Sample XMRV+
1 (75 patients with RTI)  42 None  Sputum, nasal swab  3/75 (2.3%) 
2 (31 patients with RTI)  60 COPD  BAL 1/31 (3.2%) 
3 (161 patients with RTI)  32 Immunosuppression 
after SOT or BMT 
BAL, TS  16/161 (9.9%) 
Control (62 persons with no RTI)  35 None  BAL, throat swab  2/62 (3.2%) 
*XMRV, xenotropic murine leukemia virus; +, positive for XMRV–specific sequences by PCR; RTI, respiratory tract infection; COPD, chronic obstructive 
pulmonary disease; BAL, bronchoalveolar lavage; SOT, solid organ transplantation; BMT, bone marrow transplantation; TS, tracheal secretion. 
Figure. Xenotropic murine leukemia virus–related gammaretrovirus 
(XMRV) gag sequences derived from respiratory tract secretions. 
Phylogenetic tree comparing the 390-nt gag fragment of all 
respiratory samples of this study with recently published XMRV 
sequences from patients with familial prostate cancer (1). The 
edited sequences were aligned with ClustalX version 1.82 (13,14) 
by using default settings. The tree was generated on the basis 
of positions without gaps only. Sequences are labeled as X, 
xenotropic; P, polytropic; mP, modiﬁ  ed polytropic; S, sputum, IS, 
immunosuppression; TS, tracheal secretion; and C, control. Scale 
bar indicates nucleotide substitutions per position.Among the most pressing information gaps with 
regard to XMRV is its preferred route of transmission. 
Detection of XMRV in PBMCs and plasma of patients 
with chronic fatigue syndrome raises the possibility of 
blood-borne transmission; sexual transmission has also 
been hypothesized on the basis of indirect evidence (5,9). 
We detected XMRV in respiratory secretions of immuno-
competent patients with and without RTI at a frequency 
of ≈3.2%, which is in good concordance with the recently 
reported prevalence in the general population of up to 4% 
(5). Frequency of XMRV detection in group 1 patients 
(2.25%) was comparable to that of human metapneumo-
virus and rhinovirus within this group and considerably 
less frequent than that of parainﬂ  uenzavirus (15.5%) or 
inﬂ  uenza A virus (7.6%) detection (11).
Our  ﬁ   ndings indicate that XMRV or virus-infected 
cells might be carried in and transmitted by the respira-
tory tract. Attempts to isolate infectious virus from XMRV 
sequence–positive respiratory samples failed, possibly be-
cause of inadequate storage of samples before virus cultur-
ing attempts or relatively low copy numbers of the virus 
within the samples. Thus, whether the respiratory tract 
serves as a putative transmission route for XMRV can-
not be determined at this time. The observed increase in 
prevalence among immunosuppressed patients with RTI 
suggests that XMRV might be reactivated in absence of an 
efﬁ  cient antiviral defense. Together with earlier observa-
tions on increased XMRV replication in RNase L–deﬁ  cient 
cells (1,12), this ﬁ  nding implies that the immune system 
plays a role in controlling XMRV replication. It remains 
unknown whether immunosuppression predisposes a pa-
tient to secrete infectious XMRV from the respiratory tract 
or whether presence of virus might be meaningless for epi-
demiology in a way similar to HIV-1 (15). Future studies 
should address whether the respiratory tract might serve as 
a source of XMRV infection or whether immunosuppres-
sion might cause an increased risk for primary infection.
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